Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Watch and Wait – Actualities in the Treatment of Chronic Lymphocytic Leukemia

Watch and Wait – Actualities in the Treatment of Chronic Lymphocytic Leukemia AbstractIn Western countries, chronic lymphocytic leukemia (CLL) is one of the most diagnosed leukemia types among elderly patients. CLL is described as an indolent lymphoproliferative disorder, characterized by the presence of a high number of small, mature B-cells in the peripheral blood smear, with a particular immunophenotype (CD5, CD19, CD23 positive and CD20 dim positive) and accumulation in the bone marrow and lymphoid tissue (e.g., lymph nodes, spleen). The experience of the past decades showed that CLL is clinically very heterogeneous; while some patients present a chronic clinical evolution, with a prolonged survival, in which the treatment can be delayed, others suffer from a more aggressive form, which must be treated early and is associated with many relapses. This observation led to several genomic studies that have mapped the genetic modifications involved in the disease conformations, including del(13q14), del(11q), or trisomy 12. On the other hand, certain genetic mutations such as del(17p13)–p53, NOTCH1 mutation, or ZAP70/CD38 increased expression are associated with worse clinical outcome. In order to apply the right treatment strategy, the RAI and BINET staging systems should be considered, which are based on clinical and laboratory assessment, on genetic mutations that may influence the resistance to chemotherapy, as well as the patient’s age and comorbidities. The aim of this manuscript was to present the therapeutic approaches of CLL, in order to attempt to answer the following question: to treat, or not to treat? This clinical update focuses on the managements of CLL patients in the 21st century. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Interdisciplinary Medicine de Gruyter

Watch and Wait – Actualities in the Treatment of Chronic Lymphocytic Leukemia

Download PDF
6 pages

Loading next page...
 
/lp/de-gruyter/watch-and-wait-actualities-in-the-treatment-of-chronic-lymphocytic-i9SrCxa88M
Publisher
de Gruyter
Copyright
© 2017 Szilárd Bíró et al., published by De Gruyter Open
ISSN
2501-5974
eISSN
2501-8132
DOI
10.1515/jim-2017-0097
Publisher site
See Article on Publisher Site

Abstract

AbstractIn Western countries, chronic lymphocytic leukemia (CLL) is one of the most diagnosed leukemia types among elderly patients. CLL is described as an indolent lymphoproliferative disorder, characterized by the presence of a high number of small, mature B-cells in the peripheral blood smear, with a particular immunophenotype (CD5, CD19, CD23 positive and CD20 dim positive) and accumulation in the bone marrow and lymphoid tissue (e.g., lymph nodes, spleen). The experience of the past decades showed that CLL is clinically very heterogeneous; while some patients present a chronic clinical evolution, with a prolonged survival, in which the treatment can be delayed, others suffer from a more aggressive form, which must be treated early and is associated with many relapses. This observation led to several genomic studies that have mapped the genetic modifications involved in the disease conformations, including del(13q14), del(11q), or trisomy 12. On the other hand, certain genetic mutations such as del(17p13)–p53, NOTCH1 mutation, or ZAP70/CD38 increased expression are associated with worse clinical outcome. In order to apply the right treatment strategy, the RAI and BINET staging systems should be considered, which are based on clinical and laboratory assessment, on genetic mutations that may influence the resistance to chemotherapy, as well as the patient’s age and comorbidities. The aim of this manuscript was to present the therapeutic approaches of CLL, in order to attempt to answer the following question: to treat, or not to treat? This clinical update focuses on the managements of CLL patients in the 21st century.

Journal

Journal of Interdisciplinary Medicine – de Gruyter

Published: Dec 1, 2017

References

  • Rituximab in combination with high - dose methylprednisolone for the treatment of fludarabine refractory high - risk chronic lymphocytic leukemia
    Castro
  • Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia : a randomised open label phase trial
    Hallek
  • Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia : a randomised phase trial
    Elter
  • an inhibitor of phosphatidylinositol kinase for relapsed refractory chronic lymphocytic leukemia
    Brown
  • Chemoimmunotherapy with low - dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia
    Foon
  • leukemia update on diagnosis risk stratification treatment
    Hallek
  • leukemia Update on diagnosis risk stratification treatment
    Hallek
  • Chronic lymphocytic leukaemia
    Scarfò
  • WG Ofatumumab as single - agent CD immunotherapy in fludarabine - refractory chronic lymphocytic leukemia
    Wierda
  • Long - term results of the fludarabine cyclophosphamide and rituximab regimen as initial therapy of chronic lymphocytic leukemia
    Tam
  • Pflug leukemia of
    Hallek
  • Early results of a chemoimmunotherapy regimen of fludarabine cyclophosphamide and rituximab as initial therapy for chronic lymphocytic leukemia
    Keating
  • Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
    Brown
  • Chronic lymphocytic leukaemia
    Scarfò
  • in relapsed chronic lymphocytic leukemia
    Byrd
  • Clinical staging of chronic lymphocytic leukemia
    Sawitsky
  • Management of chronic lymphocytic leukemia
    Ghia
  • Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in
    Strati
  • Marcel Upfront Treatment Options in
    Riwa
  • Autologous stem cell transplantation as first - line treatment strategy for chronic lymphocytic leukemia : a multicentre randomized controlled trial from the SFGM
    Sutton
  • Chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia results of the phase III study complement abstract
    Hillmen
  • Results of a randomized trial comparing high - dose chemotherapy plus Auto - - FC in CLL at diagnosis Marrow Transplant
    Magni
  • SEER Available at seer cancer gov csr
  • plus chlorambucil in patients with CLL and coexisting conditions
    Goede
  • Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia : a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute Working Group guidelines
    Hallek
  • Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma : an open - label multicentre phase trial
    Brien
  • Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia : a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group
    Fischer
  • a selective inhibitor of phosphatidylinositol kinase as therapy for previously treated indolent non - Hodgkin lymphoma
    Flinn
  • Montserrat JG the game is over
    Gribben
  • Managing high risk CLL during transition to a new treatment era : stem cell transplantation or novel agents
    Dreger